Live News EQUITY L impact Jul 02, 2026, 10:23 AM UTC

BTIG Reiterates Buy on Caris Life Sciences, Maintains $32 Price Target

BTIG analyst Mark Massaro reiterates Caris Life Sciences (NASDAQ: CAI ) with a Buy and maintains $32 price target.

SQUAWKNEWS Updated Jul 02, 2026, 10:23 AM UTC

BTIG analyst Mark Massaro reiterates Caris Life Sciences (NASDAQ: CAI ) with a Buy and maintains $32 price target.